Timothy L Cannon, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Vi K Chiu, Jimmy Hwang, Namrata Vijayvergia, Olatunji B Alese, Elie G Dib, Herbert L Duvivier, Kelsey A Klute, Vaibhav Sahai, Eugene R Ahn, Pablo Bedano, Deepti Behl, Sarah Sinclair, Ramya Thota, Walter J Urba, Eddy S Yang, Gina N Grantham, Dominique C Hinshaw, Abigail Gregory, Susan Halabi, Richard L Schilsky
PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results of a cohort of patients with biliary tract cancer (BTC) with ERBB2/3 amplification, overexpression, or mutation treated with pertuzumab plus trastuzumab are reported. METHODS: Eligible patients had advanced BTC, measurable disease (RECIST v1...
May 15, 2024: Journal of Clinical Oncology